



MI-2

Catalog No: tcsc0771

Available Sizes
Size: 5mg
Size: 10mg
Size: 50mg
Size: 100mg
Size: 200mg
Specifications
CAS No: 1271738-62-5
Formula: C ₁₈ H ₂₅ N ₅ S ₂
Pathway: Epigenetics
Target: Histone Methyltransferase
Purity / Grade: >98%
Solubility: 10 mM in DMSO
Alternative Names:





Observed Molecular Weight:

375.55

Product Description

MI-2 is a **Menin-MLL** interaction inhibitor with IC_{50} of 446±28 nM.

IC50 & Target: IC50: 446±28 nM (Menin-MLL)[1]

In Vitro: The menin-MLL inhibitor MI-2 very effectively blocks proliferation of MLL-AF9 and MLL-ENL transduced BMC, with $\rm GI_{50}$ values of about 5 μ M. Assessment of diverse hydrophobic groups at R1 led to the development of several compounds with $\rm IC_{50}$ values in the nanomolar range, including MI-2 ($\rm IC_{50}$ = 446±28 nM) and MI-3 ($\rm IC_{50}$ =648±25 nM). The dissociation constants measured for the menin-MLL inhibitors are at the nanomolar level, $\rm K_d$ =158 nM for MI-2. MI-2 can access the protein target and very effectively inhibit the menin-MLL-AF9 interaction in human cells. Furthermore, MI-2 shows only a small effect on the cell growth of E2A-HLF transduced BMC ($\rm GI_{50}$ >50 μ M), which may be due to inhibition of the menin interaction with wild-type MLL. Treatment with MI-2 results in $\rm GI_{50}$ values below 10 μ M in MV4;11 (harboring MLL-AF4; $\rm GI_{50}$ =9.5 μ M), KOPN-8 (MLL-ENL; $\rm GI_{50}$ =7.2 μ M) and ML-2 (MLL-AF6; $\rm GI_{50}$ =8.7 μ M), and in MonoMac6 (MLL-AF9; $\rm GI_{50}$ =18 μ M) $^{[1]}$.

All products are for RESEARCH USE ONLY. Not for diagnostic & therapeutic purposes!